140 results
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
15 May 24
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
9:01am
and arrangements we could lose rights that are important to our business; the fact that Fortress Biotech, Inc. controls a majority of the voting power of our
424B3
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement
4:53pm
a majority of the voting power of our outstanding capital stock and has rights to receive significant share grants annually; and
the risks described under … minutes from the Type C meeting with the FDA. The Type C meeting minutes indicate that the FDA and the Company are in agreement with a majority
424B5
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement for primary offering
4:52pm
, Inc. (“Fortress”) controls a majority of the voting power of our outstanding capital stock and has rights to receive significant share grants … with a majority of the proposed protocol items and are in active discussion about remaining open items. The minutes indicate that the FDA also agrees
8-K
EX-4.3
ATXI
Avenue Therapeutics Inc
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall … Stock as determined by an independent appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding
8-K
EX-10.1
6qsa7rg22
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
8-K
EX-99.1
vqsfij1p1jw3jn15r
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
8-K
EX-4.2
28ta1g4gzwwy
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
8-K
EX-4.1
jk5g y8hst
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
8-K
EX-3.1
cnk7vqaz
26 Apr 24
Avenue Therapeutics Announces Reverse Stock Split
4:39pm
8-K
EX-99.1
5jszl1jtjo7
26 Apr 24
Avenue Therapeutics Announces Reverse Stock Split
4:39pm
DEF 14C
vhsvhqdf5k2 8o
18 Mar 24
Information statement
4:59pm
8-K
EX-99.1
zd7n5
18 Mar 24
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
4:10pm
PRE 14C
kaz394y
8 Mar 24
Preliminary information
4:31pm
8-K
wk4oni19uf8yd3
8 Mar 24
Submission of Matters to a Vote of Security Holders
4:15pm
8-K
3uu7t44s
23 Feb 24
Amendments to Articles of Incorporation or Bylaws
4:17pm
8-K
EX-3.1
n312t7by5pxxb1yfc9v
23 Feb 24
Amendments to Articles of Incorporation or Bylaws
4:17pm